|

MCLA-129 Clinical Trials

2 actively recruiting trials

Pipeline

Phase 1/2: 2

Top Sponsors

  • Betta Pharmaceuticals Co., Ltd.2

Indications

  • Cancer2
  • Solid Advanced Tumor1
  • Head and Neck Cancer1
  • Solid Tumor1
  • Colorectal Cancer1

Other2 trials

Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.
Phase 1/2
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.